Low-dose growth hormone therapy reduces inflammation in HIV-infected patients: a randomized placebo-controlled study

References

• Nakagawa F, Lodwick RK, Smith CJ, et al. Projected life expectancy of people with HIV according to timing of diagnosis. AIDS. 2012;26:335–343.
   PubMed Web of Science ®Google Scholar
• Rönsholt FF, Ullum H, Katzenstein TL, et al. Persistent inflammation and endothelial activation in HIV-1 infected patients after 12 years of antiretroviral therapy. PLoS One. 2013;8:e65182.
   PubMedGoogle Scholar
• Andersen O, Haugaard SB, Andersen UB, et al. Lipodystrophy in human immunodeficiency virus patients impairs insulin action and induces defects in beta-cell function. Metabolism. 2003;52:1343–1353.
   PubMed Web of Science ®Google Scholar
• Hansen B, Petersen J, Haugaard S, et al. The prevalence of metabolic syndrome in Danish patients with HIV infection: the effect of antiretroviral therapy. HIV Med. 2009;10:378–387.
   PubMed Web of Science ®Google Scholar
• Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with HIV: a systematic review and meta-analysis. HIV Med. 2012;13:453–468.
   PubMed Web of Science ®Google Scholar
• Galli L, Salpietro S, Pellicciotta G, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012;27:657–665.
   PubMed Web of Science ®Google Scholar
• Tien PC, Choi AI, Zolopa AR, et al. Inflammation and mortality in HIV-infected adults: analysis of the FRAM study cohort. J Acquir Immune Defic Syndr. 2010;55:316–322.
   PubMed Web of Science ®Google Scholar
• Obel N, Omland LH, Kronborg G, et al. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS One. 2011;6:e22698.
   PubMed Web of Science ®Google Scholar
• Heijligenberg R, Sauerwein HP, Brabant G, et al. Circadian growth hormone secretion in asymptomatic human immune deficiency virus infection and acquired immunodeficiency syndrome. J Clin Endocrinol Metab. 1996;81:4028–4032.
   PubMed Web of Science ®Google Scholar
• Jørgensen JO, Møller N, Lauritzen T, et al. Evening versus morning injections of growth hormone (GH) in GH-deficient patients: effects on 24-hour patterns of circulating hormones and metabolites. J Clin Endocrinol Metab. 1990;70:207–214.
   PubMed Web of Science ®Google Scholar
• Andany N, Raboud JM, Walmsley S, et al. Ethnicity and gender differences in lipodystrophy of HIV-positive individuals taking antiretroviral therapy in Ontario, Canada. HIV Clin Trials. 2011;12:89–103.
   PubMed Web of Science ®Google Scholar
• Nguyen A, Calmy A, Schiffer V, et al. Lipodystrophy and weight changes: data from the Swiss HIV cohort study, 2000–2006. HIV Med. 2008;9:142–150.
   PubMed Web of Science ®Google Scholar
• Lanning NJ, Carter-Su C. Recent advances in growth hormone signaling. Rev Endocr Metab Disord. 2006;7:225–235.
   PubMed Web of Science ®Google Scholar
• Lo JC, Mulligan K, Noor MA, et al. The effects of recombinant human growth hormone on body composition and glucose metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab. 2001;86:3480–3487.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Muurahainen N, Grunfeld C, et al. Effects of growth hormone on abnormal visceral adipose tissue accumulation and dyslipidemia in HIV-infected patients. J Acquir Immune Defic Syndr. 2004;35:239–252.
   PubMed Web of Science ®Google Scholar
• Engelson ES, Glesby MJ, Mendez D, et al. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection. J Acquir Immune Defic Syndr. 2002;30:379–391.
   PubMed Web of Science ®Google Scholar
• Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785–792.
   PubMed Web of Science ®Google Scholar
• Renehan AG, Zwahlen M, Minder C, et al. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet Lond Engl. 2004;363:1346–1353.
   PubMed Web of Science ®Google Scholar
• Andersen O, Haugaard SB, Hansen BR, et al. Different growth hormone sensitivity of target tissues and growth hormone response to glucose in HIV-infected patients with and without lipodystrophy. Scand J Infect Dis. 2004;36:832–839.
   PubMed Web of Science ®Google Scholar
• Hansen BR, Kolte L, Haugaard SB, et al. Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS. 2009;23:2123–2131.
   PubMed Web of Science ®Google Scholar
• Hansen BR, Haugaard SB, Jensen FK, et al. Long-term high-physiological-dose growth hormone reduces intra-abdominal fat in HIV-infected patients with a neutral effect on glucose metabolism. HIV Med. 2010;11:266–275.
   PubMed Web of Science ®Google Scholar
• Herasimtschuk AA, Hansen BR, Langkilde A, et al. Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy. Clin Exp Immunol. 2013;173:444–453.
   PubMed Web of Science ®Google Scholar
• Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268:296–308.
   PubMed Web of Science ®Google Scholar
• Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286:327–334.
   PubMed Web of Science ®Google Scholar
• Allin KH, Bojesen SE, Nordestgaard BG. Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol. 2009;27:2217–2224.
   PubMed Web of Science ®Google Scholar
• Oliveira I, Andersen A, Furtado A, et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open. 2012;2:e001587.
   PubMed Web of Science ®Google Scholar
• Rasmussen L, Knudsen A, Katzenstein TL, et al. Soluble urokinase plasminogen activator receptor (suPAR) is a novel, independent predictive marker of myocardial infarction in HIV-1-infected patients: a nested case-control study. HIV Med. 2016;17:350–357.
   PubMed Web of Science ®Google Scholar
• Lyngbæk S, Sehestedt T, Marott JL, et al. CRP and suPAR are differently related to anthropometry and subclinical organ damage. Int J Cardiol. 2013;167:781–785.
   PubMed Web of Science ®Google Scholar
• Langkilde A, Petersen J, Klausen HH, et al. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography – a cross sectional cohort study. PLoS One. 2012;7:e51698.
   Google Scholar
• Langkilde A, Petersen J, Henriksen JH, et al. Leptin, IL-6, and suPAR reflect distinct inflammatory changes associated with adiposity, lipodystrophy and low muscle mass in HIV-infected patients and controls. Immun Ageing. 2015;12:9.
   PubMed Web of Science ®Google Scholar
• Hayek SS, Sever S, Ko YA, et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015;373:1916–1925.
   PubMed Web of Science ®Google Scholar
• Carr A, Emery S, Law M, et al. An objective case definition of lipodystrophy in HIV-infected adults: a case-control study. Lancet. 2003;361:726–735.
   PubMed Web of Science ®Google Scholar
• Andersen O, Haugaard SB, Flyvbjerg A, et al. Low-dose growth hormone and human immunodeficiency virus-associated lipodystrophy syndrome: a pilot study. Eur J Clin Invest. 2004;34:561–568.
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency. A randomized, controlled clinical trial. Ann Intern Med. 2000;133:111–122.
   PubMed Web of Science ®Google Scholar
• Sesmilo G, Miller KK, Hayden D, et al. Inflammatory cardiovascular risk markers in women with hypopituitarism. J Clin Endocrinol Metab. 2001;86:5774–5781.
   PubMed Web of Science ®Google Scholar
• Andreassen M, Vestergaard H, Kristensen LØ. Concentrations of the acute phase reactants high-sensitive C-reactive protein and YKL-40 and of interleukin-6 before and after treatment in patients with acromegaly and growth hormone deficiency. Clin Endocrinol (Oxf). 2007;67:909–916.
   PubMed Web of Science ®Google Scholar
• Han X, Sosnowska D, Bonkowski EL, et al. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology. 2005;129:185–203.
   PubMed Web of Science ®Google Scholar
• Rosenfalck AM, Maghsoudi S, Fisker S, et al. The effect of 30 months of low-dose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. J Clin Endocrinol Metab. 2000;85:4173–4181.
   PubMed Web of Science ®Google Scholar
• Swerdlow AJ, Higgins CD, Adlard P, et al. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959-85: a cohort study. Lancet Lond Engl. 2002;360:273–277.
   PubMed Web of Science ®Google Scholar
• Desai S, Landay A. Early immune senescence in HIV disease. Curr HIV/AIDS Rep. 2010;7:4–10.
   PubMedGoogle Scholar
• Capeau J. Premature aging and premature age-related comorbidities in HIV-infected patients: facts and hypotheses. Clin Infect Dis. 2011;53:1127–1129.
   PubMed Web of Science ®Google Scholar